NDA submitted for APF530 for the prevention of chemotherapy-induced nausea and vomiting - MPR
Links shared publicly online about this topic.
- 2,034total visits
NDA submitted for APF530 for the prevention of chemotherapy-induced nausea and vomiting - MPR
empr.com —
A.P. Pharma announced that it has submitted a New Drug Application (NDA) to the FDA for its lead product, APF530 (granisetron), for the prevention of both acute and delayed onset chemotherapy-induced nausea and vomiting (CINV).
View full resource at empr.com
Tags: Nausea, Vomiting, Nausea and Vomiting Medication, Drug, Pharma, FDA, Granisol, Kytril
Most Recently Shared on May 18, 2009 at 10:13 pm By:
MPR News: NDA submitted for APF530 for the prevention of chemotherapy-induced nausea and vomiting: A.P... http://tinyurl.com/ocwqll
Advertisement
